The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.
Pharmacological approaches to the treatment of ARDS are reviewed. Future treatments should be targeted at elements of the pathological process that produce specific clinical problems.
Unit of Critical Care, NHLI Division, Imperial College of Science, Technology & Medicine and Royal Brompton Hospital, London SW3 6NP, UK.
J
J
Cranshaw
M J D
MJ
Griffiths
T W
TW
Evans
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003422:Critical Care; D011464:Epoprostenol / Q000627:therapeutic use; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D016859:Lipoxygenase Inhibitors; D009569:Nitric Oxide / Q000008:administration & dosage; D010712:Phosphatidic Acids / Q000037:antagonists & inhibitors; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012128:Respiratory Distress Syndrome / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014665:Vasodilator Agents / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; D000975:Antioxidants; D016859:Lipoxygenase Inhibitors; D010712:Phosphatidic Acids; D011459:Prostaglandins E, Synthetic; D011663:Pulmonary Surfactants; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol; D013930:Thromboxane-A Synthase